Open AccessEffect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19
Author(s) -
Matthew G. Johnson,
Amy Puenpatom,
Pablo Andrés Moncada,
Lesley Burgess,
Elizabeth R Duke,
Norio Ohmagari,
Timo Wolf,
Matteo Bassetti,
Sanjay Bhagani,
Jade Ghosn,
Ying Zhang,
Hong Wan,
Angela Williams-Diaz,
Michelle Brown,
Amanda Paschke,
Carisa De Anda
Publication year - 2022
Publication title -
annals of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.839
H-Index - 390
eISSN - 1539-3704
pISSN - 0003-4819
DOI - 10.7326/m22-0729
Subject(s) - medicine , covid-19 , psychological intervention , respiratory system , intensive care medicine , betacoronavirus , virology , disease , infectious disease (medical specialty) , outbreak , nursing
In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk factors for progression to severe disease.